Epidemiologic study on prostate cancer in Sudanese men across African ethnic groups

Sci Rep. 2024 Nov 28;14(1):29646. doi: 10.1038/s41598-024-77475-7.

Abstract

This study sought to investigate the demographic and clinical characteristics of Sudanese men diagnosed with prostate cancer (PCa) to highlight differences in diagnosis among the three major ethnolinguistic groups. A total of 532 patients with confirmed PCa diagnosis through biopsy were enrolled from six medical centers in Sudan. The majority of patients, comprising 84.2% (448/532), were diagnosed with advanced-stage disease, with a Grade group above 3. There were no discernible differences in PCa aggressiveness among the ethnolinguistic groups. However, higher levels of prostate-specific antigen (PSA) were observed in the Niger-Congo group, where 55.2% had PSA values exceeding 50 ng/ml. Patients from this group were also diagnosed at a younger age. In contrast, 90.5% of Afro-Asiatic patients are over 60 years old. Further analysis conducted within an age-matched subgroup of patients (n = 273) revealed a higher incidence of perineural invasion in the Afro-Asiatic group. This research represents the first investigation of PCa across different African ethnic groups and associates a higher incidence of perineural invasion with a specific ethnic group. While recent efforts have been made to establish African-relevant risk models to mitigate PCa health disparities, there remains a need for further investigation into genetically distinct populations within the African continent.

Keywords: Afro-Asiatic; Incidence; Niger-Congo; Nilo-Saharan; Perineural invasion; Prostate cancer; Sudan.

MeSH terms

  • Aged
  • Black People
  • Epidemiologic Studies
  • Ethnicity
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms* / blood
  • Prostatic Neoplasms* / epidemiology
  • Prostatic Neoplasms* / ethnology
  • Prostatic Neoplasms* / pathology
  • Sudan / epidemiology
  • Sudan / ethnology

Substances

  • Prostate-Specific Antigen